poster

Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder: A Randomized, Double-blind, Fixed-dose Trial

Background: In a previous flexible dose study, dasotraline, a long-acting dopamine/ norepinephrine reuptake inhibitor, demonstrated significant efficacy in the treatment of binge-eating d...

11/22/2019

A Retrospective Cohort Study of Suicidality Among Patients With Binge Eating Disorder

Individuals diagnosed with binge eating disorder (BED) are at higher risk of suicidality than those not diagnosed with BED. This study estimated the incidence (per 1000 person-years) of s...

11/22/2019

Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension (AMPH EROS) in the Treatment of Children With Attention-Deficit/Hyperactivity Disorder

Objective: Determine if AMPH EROS has an onset of effect at 30 minutes post-dose in children with ADHD.

11/22/2019

Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder With Adjunctive Pimavanserin

Sexual dysfunction occurs in 40%-60% of patients with major depressive disorder (MDD), due to either the illness itself and/or the effects of antidepressant treatment. The phase-2 CLARITY...

11/22/2019

Number Needed to Treat Analysis of the SAGE-217 Phase 2 Clinical Trial Results in Major Depressive Disorder

Background: SAGE-217 is a novel, positive allosteric modulator of GABA(A) receptors under development in Major Depressive Disorder (MDD). This analysis quantified the number needed to tre...

11/22/2019

A Qualitative Assessment of Reasons for Frequent Emergency Department Utilization Among Patients With Serious Mental Illness

Objective: Characterize drivers of frequent emergency department use and barriers to mental and primary healthcare among individuals diagnosed with serious mental illness at a large, urba...

11/22/2019

Exploring Patient Experiences Taking Adjunctive Brexpiprazole for Major Depressive Disorder (MDD): Post-hoc Analysis of Exit Interview Data

Background: The efficacy and safety of adjunctive brexpiprazole, a serotonin–dopamine activity modulator, has been demonstrated in clinical studies in adults with MDD and inadequate respo...

11/22/2019

A Combination of Olanzapine and Samidorphan Has No Clinically Relevant Effect on QT Prolongation Up to Supratherapeutic Doses

Background: ALKS 3831, a combination of olanzapine and samidorphan (OLZ/SAM) in development for schizophrenia, is intended to mitigate olanzapine-associated weight gain. This thorough QT ...

11/22/2019

Use of Patient Health Questionnaire to Predict Relapses Among Patients With Treatment-Resistant Depression Treated With Esketamine + Oral Antidepressant

Objective: To assess the Patient Health Questionnaire (PHQ-9) as a predictor of relapse of depressive symptoms in treatment-resistant depression (TRD).

11/22/2019

Efficacy and Safety of an Asenapine Transdermal System (HP-3070) for Treatment of Adults with Schizophrenia: A Phase 3 Randomized, Placebo-Controlled, Inpatient Study

Background: HP-3070, an asenapine transdermal patch for schizophrenia, offers favorable pharmacokinetics with minimal peak and trough fluctuations.

11/22/2019

Tracks

Schizophrenia Insights

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products